Effect of beta(2)-microglobulin adsorption column on dialysis-related amyloidosis

Kidney Int. 2003 Oct;64(4):1522-8. doi: 10.1046/j.1523-1755.2003.00235.x.


Background: beta2-microglobulin (beta2-m) is considered a major pathogenic factor in dialysis-related amyloidosis (DRA), often seen in long-term dialysis patients. No effective therapy for this severely debilitating disease is currently available. Lixelle, an adsorption column, has been developed for the elimination of beta2-m; the efficacy of this column has been evaluated in this study.

Methods: Seventeen hemodialysis patients with DRA were first treated with high-flux dialysis for a minimum of 1 year. This was followed by 1-year treatment with Lixelle column connected in series to the high-flux dialyzer. Treatments were used three times a week for both phases of this study. During the study period, beta2-m, pinch strength, motor terminal latency, and activities of daily living were evaluated.

Results: After 1-year treatment with high-flux dialysis the beta2-m level remained unchanged; however, after 1-year treatment with the addition of the Lixelle column, beta2-m level decreased significantly from 34.5 +/- 8.4 mg/L to 28.8 +/- 7.3 mg/L (P < 0.05). After 1 year of Lixelle column use, the pinch strength increased from 6.8 +/- 4.7 pounds to 9.1 +/- 5.5 pounds (P < 0.01), and the median motor terminal latency was significantly reduced from 5.1 +/- 1.0 mseconds to 4.5 +/- 1.1 mseconds. A significant improvement was also observed in the activities of daily living score of the upper extremities.

Conclusion: These results suggest that the addition of Lixelle to the high-flux dialyzer is associated with a significant clinical improvement in DRA patients.

Publication types

  • Clinical Trial

MeSH terms

  • Adsorption
  • Adult
  • Aged
  • Amyloidosis / blood
  • Amyloidosis / etiology*
  • Amyloidosis / therapy*
  • Blood Component Removal / instrumentation*
  • Blood Component Removal / methods*
  • Equipment Design
  • Female
  • Humans
  • Male
  • Middle Aged
  • Renal Dialysis / adverse effects*
  • Treatment Outcome
  • beta 2-Microglobulin / metabolism*


  • beta 2-Microglobulin